The US FDA will consider whether innovator biologics exclusivity should receive similar treatment as small molecule drugs as part of efforts to enhance biosimilar development and availability.
Agency officials will accept public comments on many biosimilar-related issues during a Sept. 4 public hearing at FDA's White Oak...






